Drug Trials Snapshots: VONJO

Why It Matters

VONJO offers the first targeted option for a high‑risk myelofibrosis subset that cannot tolerate existing JAK inhibitors, potentially expanding treatment access and improving survival outcomes.

Key Takeaways

• FDA approved VONJO for low‑platelet myelofibrosis (≤50,000/µL).
• 29% VONJO patients hit ≥35% spleen shrinkage vs 3% BAT.
• Benefit larger in patients ≥65 years (36.8% response).
• Most common adverse events: diarrhea, thrombocytopenia, nausea, anemia.
• Trial enrolled 63 low‑platelet patients from 311 total; 31 received VONJO.

Pulse Analysis

Myelofibrosis, a rare bone‑marrow disorder, often progresses to severe splenomegaly and cytopenias, leaving patients with limited therapeutic choices. Those with platelet counts below 50,000/µL are especially vulnerable because standard JAK inhibitors such as ruxolitinib can exacerbate bleeding risk. VONJO (pacritinib) targets the JAK2/FLT3 pathway while sparing platelet production, positioning it as a biologically rational option for this high‑risk cohort. By delivering a twice‑daily oral capsule, the drug simplifies administration compared with intravenous regimens, aligning with the growing demand for patient‑friendly oncology therapies.

The pivotal trial enrolled 311 myelofibrosis patients, but efficacy was assessed in the 63 participants with the lowest platelet counts. VONJO demonstrated a 29% rate of ≥35% spleen volume reduction at 24 weeks, starkly outperforming the 3% observed with best available therapy, which included a mix of conventional agents and watch‑and‑wait approaches. Subgroup analysis revealed a pronounced benefit in patients aged 65 and older, where 36.8% responded versus 4% on comparator. These data underpin the FDA’s accelerated approval, granting earlier market entry while a confirmatory study continues to verify long‑term clinical benefit.

Safety remains a key consideration; the most frequent adverse events were diarrhea, thrombocytopenia, nausea, and anemia, with grade 3 or higher thrombocytopenia occurring in roughly one‑third of treated patients. While serious cardiac and infectious complications were reported, their incidence was comparable to the control arm. As VONJO integrates into treatment algorithms, hematologists will weigh its efficacy against the heightened bleeding risk, especially in older patients who dominate the trial population. Ongoing Phase III data will be critical to solidify its role and potentially expand indications beyond the current low‑platelet niche, influencing both prescribing patterns and the competitive landscape of myelofibrosis therapeutics.